SpringerLink
Log in

Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin’s lymphoma

A comparison of doxorubicin and pirarubicin: a randomized phase II study

  • Original Paper
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Purpose

To compare the efficacy and safety of a biweekly CHOP regimen consisting of cyclophosphamide (CPA), doxorubicin (DOX), vincristine (VCR), and prednisolone (PSL) and those of a biweekly THP-COP regimen containing pirarubicin (THP), an anthracyclin with less cardiotoxicity than DOX.

Methods

A prospective, randomized phase II study with 80 patients (40 receiving CHOP or THP-COP) less than 70 years of age with previously untreated aggressive non-Hodgkin’s lymphoma (NHL). The regimens consisted of DOX or THP 50 mg/m2, CPA 750 mg/m2, VCR 1.4 mg/m2, and PSL 100 mg/body administered for 5 days every 2 weeks for eight cycles.

Results

No significant differences in known prognostic factors were found between the two groups. Complete remission rate was 72.5% (72.5% for CHOP, 72.5% for THP-COP). The 5-year overall survival rate was 49.2% (43.7% for CHOP, 54.0% for THP-COP). When the patients were divided into groups with favorable or poor prognostic factors according to the International Prognostic Index, survival of the former group (L/LI) was superior to that of the later group (HI/H), regardless of chemotherapy regimen (P<0.001). Although grade 3 cardiotoxicity occurred in one patient in the CHOP group, no fatal toxic reactions occurred in either group. The THP-COP produced results equivalent to those of CHOP regarding efficacy and safety in aggressive NHL patients less than 70 years of age.

Conclusions

Although both regimens effectively treated those patients with favorable prognostic factors, neither was satisfactory for treating those with poor prognostic factors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2a, b
Fig. 3a, b

Similar content being viewed by others

References

  • Aoki S, Tsukada N, Nomoto N, Maruyama S, Takahashi M, Moriyama Y, Shibata A, Aizawa Y (1998) Effect of pirarubicin for elderly patients with malignant lymphoma. J Exp Clin Cancer Res 17:465–470

    CAS  PubMed  Google Scholar 

  • Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M (1971) Report of the committee on Hodgkin’s disease staging classification. Cancer Res 31:1860–1861

    CAS  PubMed  Google Scholar 

  • Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Kippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an International Workshop to standardize response criteria for non-Hodgkin’s lymphomas. J Clin Oncol 17:1244–1253

    CAS  PubMed  Google Scholar 

  • Cox DR (1972) Regression models and life-tables (with discussions). J Roy Stat Soc (Series B) 34:187–220

    Google Scholar 

  • DeVita VT Jr, Hubbard SM, Longo DL (1987) The chemotherapy of lymphomas: looking back, moving forward—The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 47:5810–5824

    PubMed  Google Scholar 

  • Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA, Miller TP (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med 328:1002–1006

    CAS  PubMed  Google Scholar 

  • Gianni AS, Bregni M, Siena S, Brambilla C, Nicola MD, Lombardi F, Gandola L, Tarella C, Pileri A, Ravagnani F, Valagussa P, Bonadonna G (1997) High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 336:1290–1297

    CAS  PubMed  Google Scholar 

  • Haioun C, Lepage E, Gisselbrecht C, Bastion Y, Coiffier B, Brice P, Bosly A, Dupriez B, Nouvel C, Tilly H, Lederlin P, Biron P, Briere J, Gaulard P, Reyes F for the Group d’Etude des Lymphomes de I’Adulte (1997) Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin’s lymphoma: updated results of the prospective study LNH87–2. J Clin Oncol 15:1131–1137

    CAS  PubMed  Google Scholar 

  • Haioun C, Lepage E, Gisselbrecht C, Salles G, Coiffier B, Brice P, Bosly A, Morel P, Nouvel C, Tilly H, Lederlin P, Sebban C, Briere J, Gaulard P, Reyes F (2000) Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin’s lymphoma: final analysis of the prospective LNH87–2 protocol—a Group d’Etude des Lymphomes de I’Adulte Study. J Clin Oncol 18:3025–3030

    CAS  PubMed  Google Scholar 

  • Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) (2001) World Health Organization classification of tumors, pathology and genetics. Tumors of haematopoietic and lymphoid tissues. IARC Lyon, pp 109–236

  • Kaplan EL, Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457–481

    Google Scholar 

  • Kitamura K, Takaku F (1990) Pirarubicin, a novel derivative of doxorubicin, in THP-COP therapy for non-Hodgkin’s lymphoma in the elderly. Am J Clin Oncol 13[Suppl]:S15-S19

  • Kwak LW, Halpern J, Olshen RA, Horning SJ (1990) Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 8:963–977

    CAS  PubMed  Google Scholar 

  • Miller AA, Salewski E (1994) Prospects for pirarubicin. Med Pediatr Oncol 22:261–268

    CAS  PubMed  Google Scholar 

  • Niitsu N, Umeda M (1997) THP-COPBLM (pirarubicin, cyclophosphamide, vincristine, prednisone, bleomycin and procarbazine) regimen combined with granulocyte colony-stimulating factor (G-CSF) for non-Hodgkin’s lymphoma in elderly patients: a prospective study. Leukemia 11:1817–1820

    Article  CAS  PubMed  Google Scholar 

  • Niitsu N, Umeda M (1998) Biweekly THP-COPBLM (pirarubicin, cyclophosphamide, vincristine, prednisone, bleomycin, and procarbazine) regimen combined with granulocyte colony-stimulating factor (G-CSF) for intermediate and high grade non-Hodgkin’s lymphoma. Leukemia 12:1457–1460

    Article  CAS  PubMed  Google Scholar 

  • Niitsu N, Umeda M (1999) Response and adverse drug reactions to combination chemotherapy in elderly patients with aggressive non-Hodgkin’s lymphoma: comparison of CHOP, COP-BLAM, COP-BLAM III, and THP-COPBLM. Eur J Haematol 63:337–344

    CAS  PubMed  Google Scholar 

  • Niitsu N, Okamoto M, Kuraishi Y, Nakamura S, Kodama F, Hirano M, The Adult Lymphoma Treatment Study Group (2000) CyclOBEAP (cyclophosphamide, vincristine, bleomycin, etoposide, doxorubicin, prednisolone) regimen with granulocyte colony-stimulating factor (G-CSF) for patients with aggressive non-Hodgkin’s lymphoma: a pilot study. Eur J Haematol 65:188–194

    CAS  PubMed  Google Scholar 

  • Santoro A, Balzarotti M, Tondini C, Zanini M, Giardini R, Latteri F, Rampinelli I, Bufalino R (1999) Dose-escalation of CHOP in non-Hodgkin’s lymphoma. Ann Oncol 10:519–525

    Article  CAS  PubMed  Google Scholar 

  • Sawada M, Tsurumi H, Yamada T, Hara T, Fukuno K, Goto H, Shimizu M, Kasahara S, Yoshikawa T, Kanemura N, Oyama M, Takami T, Moriwaki H (2002) A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin’s lymphoma who had previously received CHOP therapy as first-line chemotherapy. Eur J Haematol 68:354–361

    Article  CAS  PubMed  Google Scholar 

  • Shipp MA, Neuberg D, Janicek M, Canellos GP, Shulman LN (1995) High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin’s lymphoma: a dose-finding pilot study. J Clin Oncol 13:2916–2923

    CAS  PubMed  Google Scholar 

  • Takagi T, Oguro M (1987) (2”-R)-4’-o-Tetrahydropyranyladriamycin, a new anthracyclin derivative; its effectiveness in lymphoid malignancies. Cancer Chemother Pharmacol 20:151–154

    CAS  PubMed  Google Scholar 

  • Takagi T, Sakai C, Oguro M (1990) Combination chemotherapy with pirarubicin (THP), cyclophosphamide, vincristine, and prednisolone (VEP-THP therapy) in the treatment of non-Hodgkin’s lymphoma. Oncology 47:25–28

    CAS  PubMed  Google Scholar 

  • Tanosaki R, Okamoto S, Akatsuka N, Ishida A, Michikawa N, Masuda Y, Uchida H, Murata M, Kizaki M, Ikeda Y (1994) Dose escalation of biweekly cyclophosphamide, doxorubicin, vincristine, and prednisolone using recombinant human granulocyte colony stimulating factor in non-Hodgkin’s lymphoma. Cancer 74:1939–1944

    CAS  PubMed  Google Scholar 

  • The International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329:987–994

    PubMed  Google Scholar 

  • The non-Hodgkin’s lymphoma pathologic classification project (1982) National Cancer Institute-sponsored study of classifications of non-Hodgkin’s lymphomas. Summary and description of a working formulation for clinical usage. Cancer 49:2112–2135

    PubMed  Google Scholar 

  • Umezawa H, Takahashi Y, Kinoshita M, Naganawa H, Masuda T, Ishizuka M, Tatsuta K, Takeuchi T (1979) Tetrahydropyranyl derivatives of daunomycin and adriamycin. J Antibiot 32:1082–1084

    CAS  PubMed  Google Scholar 

  • Witzig TE, Camoriano JK, Schroeder G, Kurtin PJ, Habermann TM (1998) A phase I trial of high-dose ProMACE-CytaBOM with granulocyte colony stimulating factor for patients with non-Hodgkin’s lymphoma. Leukemia Lymphoma 28:307–314

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. First Department of Internal Medicine, Gifu University School of Medicine, 40 Tsukasa-machi, 500–8705, Gifu, Japan

    Hisashi Tsurumi, Toshiki Yamada, Michio Sawada, Nobuhiro Kanemura, Yasushi Kojima, Takeshi Hara & Hisataka Moriwaki

  2. Department of Cellular Pathology, Gifu University School of Medicine, Gifu, Japan

    Hisashi Tsurumi, Yasushi Kojima, Masanao Saio & Tsuyoshi Takami

  3. Department of Internal Medicine, Kisogawa Hospital, Kisogawa, Japan

    Senji Kasahara & Masami Oyama

  4. Department of Internal Medicine, Takayama Red Cross Hospital, Takayama, Japan

    Kenji Fukuno

  5. Department of Hematology, Jichi Medical School, Tochigi, Japan

    Takeshi Hara & Keiya Ozawa

  6. Department of Hematology, Gifu Municipal Hospital, Gifu, Japan

    Takeshi Takahashi

Authors
  1. Hisashi Tsurumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Toshiki Yamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michio Sawada
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Senji Kasahara
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nobuhiro Kanemura
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yasushi Kojima
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kenji Fukuno
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Takeshi Hara
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Masanao Saio
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Takeshi Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Masami Oyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Keiya Ozawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Tsuyoshi Takami
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Hisataka Moriwaki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hisataka Moriwaki.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tsurumi, H., Yamada, T., Sawada, M. et al. Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin’s lymphoma. J Cancer Res Clin Oncol 130, 107–113 (2004). https://doi.org/10.1007/s00432-003-0508-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-003-0508-9

Keywords

Search

Navigation